OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation
Gerasimos Filippatos, Dimitrios Farmakis, Javed Butler, et al.
European Journal of Heart Failure (2023) Vol. 25, Iss. 7, pp. 970-977
Open Access | Times Cited: 22
Gerasimos Filippatos, Dimitrios Farmakis, Javed Butler, et al.
European Journal of Heart Failure (2023) Vol. 25, Iss. 7, pp. 970-977
Open Access | Times Cited: 22
Showing 22 citing articles:
Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference
Dominik Linz, Jason G. Andrade, Elena Arbelo, et al.
EP Europace (2024) Vol. 26, Iss. 4
Open Access | Times Cited: 33
Dominik Linz, Jason G. Andrade, Elena Arbelo, et al.
EP Europace (2024) Vol. 26, Iss. 4
Open Access | Times Cited: 33
2024 update in heart failure
Alberto Beghini, Antonio Maria Sammartino, Z. Papp, et al.
ESC Heart Failure (2024)
Open Access | Times Cited: 31
Alberto Beghini, Antonio Maria Sammartino, Z. Papp, et al.
ESC Heart Failure (2024)
Open Access | Times Cited: 31
Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure
Joshua Newman, Eileen O’Meara, Michael Böhm, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 9, pp. 932-950
Closed Access | Times Cited: 23
Joshua Newman, Eileen O’Meara, Michael Böhm, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 9, pp. 932-950
Closed Access | Times Cited: 23
Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy
Pablo García‐Pavía, Artur Oręziak, Ahmad Masri, et al.
European Heart Journal (2024)
Open Access | Times Cited: 15
Pablo García‐Pavía, Artur Oręziak, Ahmad Masri, et al.
European Heart Journal (2024)
Open Access | Times Cited: 15
Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction
Subodh Verma, Javed Butler, Barry A. Borlaug, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 17, pp. 1603-1614
Open Access | Times Cited: 12
Subodh Verma, Javed Butler, Barry A. Borlaug, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 17, pp. 1603-1614
Open Access | Times Cited: 12
Impact of sodium-glucose cotransporter 2 inhibitors on catheter ablation for atrial fibrillation in heart failure patients without type-2 diabetes
Masafumi Harada, Yuji Motoike, Y. Nomura, et al.
International Journal of Cardiology (2025) Vol. 422, pp. 132954-132954
Open Access | Times Cited: 1
Masafumi Harada, Yuji Motoike, Y. Nomura, et al.
International Journal of Cardiology (2025) Vol. 422, pp. 132954-132954
Open Access | Times Cited: 1
Sodium–glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis
Hongda Zhang, Lei Ding, Lijie Mi, et al.
European Journal of Preventive Cardiology (2023) Vol. 31, Iss. 7, pp. 770-779
Closed Access | Times Cited: 20
Hongda Zhang, Lei Ding, Lijie Mi, et al.
European Journal of Preventive Cardiology (2023) Vol. 31, Iss. 7, pp. 770-779
Closed Access | Times Cited: 20
Effects of Heart Failure Therapies on Atrial Fibrillation: Biological and Clinical Perspectives
Alfredo Mauriello, Antonia Ascrizzi, Anna Selvaggia Roma, et al.
Antioxidants (2024) Vol. 13, Iss. 7, pp. 806-806
Open Access | Times Cited: 5
Alfredo Mauriello, Antonia Ascrizzi, Anna Selvaggia Roma, et al.
Antioxidants (2024) Vol. 13, Iss. 7, pp. 806-806
Open Access | Times Cited: 5
CMR assessment of epicardial edipose tissue in relation to myocardial inflammation and fibrosis in patients with new-onset atrial arrhythmias after STEMI
Yanfei Ren, Xinjia Du, Maochen Li, et al.
BMC Cardiovascular Disorders (2025) Vol. 25, Iss. 1
Open Access
Yanfei Ren, Xinjia Du, Maochen Li, et al.
BMC Cardiovascular Disorders (2025) Vol. 25, Iss. 1
Open Access
Sex Differences in Clinical Characteristics and Management of Non-valvular Atrial Fibrillation in a Resource-Limited Setting
F. Baez, G. Mejía, Julia Ramírez, et al.
Cureus (2025)
Open Access
F. Baez, G. Mejía, Julia Ramírez, et al.
Cureus (2025)
Open Access
Atrial Fibrillation (AF) and Heart Failure With Preserved Ejection Fraction (HFpEF): Advances and Challenges
Sanjeev Saksena, April Slee, Ranghadham Nagarakanti, et al.
Journal of Cardiovascular Electrophysiology (2025)
Open Access
Sanjeev Saksena, April Slee, Ranghadham Nagarakanti, et al.
Journal of Cardiovascular Electrophysiology (2025)
Open Access
Emerging horizons: clinical applications and multifaceted benefits of SGLT-2 inhibitors beyond diabetes
Qing Feng, Moya Wu, Zizhao Mai
Frontiers in Cardiovascular Medicine (2025) Vol. 12
Open Access
Qing Feng, Moya Wu, Zizhao Mai
Frontiers in Cardiovascular Medicine (2025) Vol. 12
Open Access
Finerenone and Atrial Fibrillation in Heart Failure
Shingo Matsumoto, Alasdair Henderson, Pardeep S. Jhund, et al.
JAMA Cardiology (2025)
Closed Access
Shingo Matsumoto, Alasdair Henderson, Pardeep S. Jhund, et al.
JAMA Cardiology (2025)
Closed Access
Screening for Unrecognized HFpEF in Atrial Fibrillation and for Unrecognized Atrial Fibrillation in HFpEF
Yogesh N.V. Reddy, Peter A. Noseworthy, Barry A. Borlaug, et al.
JACC Heart Failure (2024) Vol. 12, Iss. 6, pp. 990-998
Closed Access | Times Cited: 4
Yogesh N.V. Reddy, Peter A. Noseworthy, Barry A. Borlaug, et al.
JACC Heart Failure (2024) Vol. 12, Iss. 6, pp. 990-998
Closed Access | Times Cited: 4
Impact of Sodium-glucose Cotransporter 2 Inhibitor on Recurrence and Cardiovascular Outcomes after Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure
Zixu Zhao, Yiping Wang, Chao Jiang, et al.
Heart Rhythm (2024)
Closed Access | Times Cited: 2
Zixu Zhao, Yiping Wang, Chao Jiang, et al.
Heart Rhythm (2024)
Closed Access | Times Cited: 2
Rapid Uptitration of Guideline-Directed Medical Therapies in Acute Heart Failure With and Without Atrial Fibrillation
Dimitrios Farmakis, Beth A. Davison, Katerina Fountoulaki, et al.
JACC Heart Failure (2024) Vol. 12, Iss. 11, pp. 1845-1858
Closed Access | Times Cited: 1
Dimitrios Farmakis, Beth A. Davison, Katerina Fountoulaki, et al.
JACC Heart Failure (2024) Vol. 12, Iss. 11, pp. 1845-1858
Closed Access | Times Cited: 1
Atrial Fibrillation in Heart Failure: Novel Insights, Challenges, and Treatment Opportunities
Ghassan Bidaoui, Ala Assaf, Nassir Marrouche
Current Heart Failure Reports (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Ghassan Bidaoui, Ala Assaf, Nassir Marrouche
Current Heart Failure Reports (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Therapeutic effects of sodium–glucose cotransporter 2 inhibitors in patients with heart failure with preserved ejection fraction: From outcome improvement to potentially favourable influences on atrial fibrillation burden, atrial fibrillation progression and atrial cardiomyopathy
Giuseppe Boriani, Davide Antonio Mei, Jacopo Francesco Imberti
European Journal of Heart Failure (2023) Vol. 25, Iss. 7, pp. 978-980
Closed Access | Times Cited: 3
Giuseppe Boriani, Davide Antonio Mei, Jacopo Francesco Imberti
European Journal of Heart Failure (2023) Vol. 25, Iss. 7, pp. 978-980
Closed Access | Times Cited: 3
Regional expert opinion: Management of heart failure with preserved ejection fraction in the Middle East, North Africa and Turkey
Magdy Abdelhamid, Kamal Al Ghalayini, Khaldoon A Alhumood, et al.
ESC Heart Failure (2023) Vol. 10, Iss. 5, pp. 2773-2787
Open Access | Times Cited: 2
Magdy Abdelhamid, Kamal Al Ghalayini, Khaldoon A Alhumood, et al.
ESC Heart Failure (2023) Vol. 10, Iss. 5, pp. 2773-2787
Open Access | Times Cited: 2
Meta-analysis of the efficacy and impact on cardiac function of sodium–glucose cotransporter 2 inhibitor Empagliflozin in heart failure patients
Weidong Li, Xuanyang Shen, Meiqi Zhang, et al.
Medicine (2024) Vol. 103, Iss. 45, pp. e40409-e40409
Open Access
Weidong Li, Xuanyang Shen, Meiqi Zhang, et al.
Medicine (2024) Vol. 103, Iss. 45, pp. e40409-e40409
Open Access
Comparative Analysis of the Influence of Empagliflozin and Dapagliflozin on the Course of Heart Failure with Associated Pathology
N.M. Kulaiets
Ukrainian journal of cardiovascular surgery (2024) Vol. 32, Iss. 4, pp. 40-51
Open Access
N.M. Kulaiets
Ukrainian journal of cardiovascular surgery (2024) Vol. 32, Iss. 4, pp. 40-51
Open Access
July 2023 at a glance: heart failure with preserved ejection fraction and comorbidities
Daniela Tomasoni, Marianna Adamo, Marco Metra
European Journal of Heart Failure (2023) Vol. 25, Iss. 7, pp. 925-928
Closed Access
Daniela Tomasoni, Marianna Adamo, Marco Metra
European Journal of Heart Failure (2023) Vol. 25, Iss. 7, pp. 925-928
Closed Access
